<DOC>
	<DOCNO>NCT02491697</DOCNO>
	<brief_summary>The prognosis advance breast cancer improve much recently although varies adjuvant drug tried.Dendritic cell co-cultured cytokine-induced killer cell ( DC-CIK ) immunotherapy prove improve survival several cancer , role advance breast cancer stain unclear . The purpose study evaluate efficacy safety DC-CIK immunotherapy combine capecitabine versus capecitabine monotherapy treatment advance breast cancer .</brief_summary>
	<brief_title>Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy Advanced Breast Cancer</brief_title>
	<detailed_description>1.400 patient advanced breast cancer definitively diagnosis base histopathology , accord 7th American Joint Committee Cancer ( AJCC ) Cancer Staging Manual . 2.All patient randomly divide group A（DC-CIK immunotherapy combine capecitabine ) group B（capecitabine monotherapy ) . 3.Patients group A receive 4 cycle DC-CIK treatment ( every 1 year ) capecitabine ( continuous ) .Patients group B receive capecitabine monotherapy ( continuous ) . 4.The response assess use Response Evaluation Criteria Solid Tumor Group ( RECIST ) guideline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically confirm advanced breast cancer . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Hemoglobin≥10.0g/dL , Neutrophil count≥1.5×10^9/L , Platelet count≥75×10^9/L ; total bilirubin ( TBIL ) ≤1.5×ULN ; alkaline phosphatase ( AKP ) , aspartate aminotransferase ( AST ) , ALT≤2.5×ULN ( without metastasis liver ) , AKP , AST , ALT≤5×ULN ( metastasis liver ) ; BUN≤1.5×ULN , Cr≤1.5×ULN . Patient receive 12 kind cytotoxic chemotherapy previously . Patient never receive capecitabine oral fluorouracil . Patients suffer serious organ dysfunction . HIV positive immunodeficiency disease . Patients use long time use immunosuppressant drug . Patients active infection . Patients allergic fluorouracil . Pregnant lactating woman . History malignancy . Other situation researcher consider unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>DC-CIK</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Capecitabine</keyword>
</DOC>